Table I.
Characteristics of the colorectal tumor samples collected from the cetuximab-treated patients with the RAS and BRAFV600 wild-type who underwent RNA-sequencing testing.
| Category | Valuesa |
|---|---|
| Age, years | 58 (22–80)b |
| Sex | |
| Male | 57 (62%) |
| Female | 35 (38%) |
| Lines of treatment | |
| 1 | 75 (82%) |
| ≥2 | 17 (18%) |
| Regimen | |
| Cetuximab | 5 (5%) |
| Cetuximab + irinotecan | 12 (13%) |
| Cetuximab + FOLFIRI | 66 (72%) |
| Cetuximab + FOLFOX | 9 (10%) |
| Primary site | |
| Right | 19 (21%) |
| Left | 73 (79%) |
| Test for RAS and BRAFV600 mutations status | |
| Sanger sequencing | 15 (16%) |
| Next-generation sequencing | 77 (84%) |
| Initial stage | |
| Stage I–III | 10 (11%) |
| Stage IV | 82 (89%) |
| MSI status | |
| MSI-H | 1 (1%) |
| MSI-L | 3 (3%) |
| MSS or pMMR | 86 (93%) |
| Not tested | 2 (2%) |
| Progression-free survival | |
| First line, months | 13.48 (12.66-14.66)c |
| ≥Second line or more, months | 6.46 (1.57-9.41)c |
| Clinical status of samples (n=111) | |
| Pre-treatment, CR/PR | 59 (53%) |
| Pre-treatment, SD/PD | 16 (14%) |
| Post-treatment, non-PD | 16 (14%) |
| Post-treatment, PD | 20 (18%) |
| Tumor sample origin (n=111) | |
| Primary tumor | 84 (76%) |
| Metastasis | 27 (24%) |
| Neurofibromin 1 mRNA expression, | |
| FPKM | 51.14±12.71d |
a
Data presented as N (%) unless otherwise stated.
b
Data presented as median (range).
c
Data presented as n (95% CI).
d
Data presented as the mean ± standard deviation. FOLFIRI, 5-fluorouracil, folinic acid and irinotecan; FOLFOX, 5-fluorouracil, folinic acid and oxaliplatin; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; pMMR, proficient mismatch repair; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; FPKM, Fragments Per Kilobase of transcript per million.